

JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC

Balance Sheet

As at 31 March,	Notes No.	2016	2016	2015	2015
		CAD	INR (' In Thousands)	CAD	INR (' In Thousands)
<b>I. EQUITY AND LIABILITIES</b>					
<b>Shareholders' Funds</b>					
Share capital	1	50,000	2,452	50,000	2,452
Reserves and surplus	2	66,221	3,502	94,186	4,617
		<b>116,221</b>	<b>5,954</b>	<b>144,186</b>	<b>7,070</b>
<b>Current liabilities</b>					
Trade payables	3	51	3	4,377	215
Other current liabilities	4	7,999	409	65,534	3,213
Short-term provisions	5	-	-	15,269	749
		<b>8,050</b>	<b>412</b>	<b>85,179</b>	<b>4,176</b>
<b>Total</b>		<b>124,271</b>	<b>6,366</b>	<b>229,365</b>	<b>11,246</b>
<b>II. ASSETS</b>					
<b>Non-current assets</b>					
Long-term loans and advances	6	332	17	-	-
		<b>332</b>	<b>17</b>	-	-
<b>Current assets</b>					
Cash and bank balances	7	123,939	6,349	229,365	11,246
		<b>123,939</b>	<b>6,349</b>	<b>229,365</b>	<b>11,246</b>
<b>Total</b>		<b>124,271</b>	<b>6,366</b>	<b>229,365</b>	<b>11,246</b>

**Prakash C Bisht**

CFO (Ingredients) & Sr. VP (Group Accounts)

Place: Noida

Date: 23 May, 2016

JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC  
Statement of Profit and Loss

For the year ended 31 March,	Notes No.	2016		2015	
		CAD	INR (' In Thousands)	CAD	INR (' In Thousands)
<b>REVENUE</b>					
Revenue from operations (Gross)	8	57,535	2,840	154,155	7,763
Other income	9	-	-	316	18
<b>Total revenue</b>		<b>57,535</b>	<b>2,840</b>	<b>154,471</b>	<b>7,781</b>
<b>EXPENSES</b>					
Other expenses	10	85,500	4,284	98,705	5,416
<b>Total expenses</b>		<b>85,500</b>	<b>4,284</b>	<b>98,705</b>	<b>5,416</b>
<b>(Loss)/ Profit before exceptional items and tax</b>		<b>(27,965)</b>	<b>(1,444)</b>	<b>55,766</b>	<b>2,365</b>
Exceptional items	11	-	-	9,587	491
<b>(Loss)/ Profit before tax</b>		<b>(27,965)</b>	<b>(1,444)</b>	<b>46,179</b>	<b>1,874</b>
Tax expenses:					
- Current tax		-	-	12,422	626
- Deferred tax charge/(credit)		-	-	-	-
		-	-	<b>12,422</b>	<b>626</b>
<b>(Loss)/ Profit for the Year</b>		<b>(27,965)</b>	<b>(1,444)</b>	<b>33,757</b>	<b>1,248</b>

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)

Place: Noida

Date: 23 May, 2016

**JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC**  
**Cash flow Statement for the Year Ended 31 March,**

Particulars	2016		2015	
	CAD	INR (' In Thousands)	CAD	INR (' In Thousands)
<b>Cash flows from operating activities</b>				
Net (Loss)/ Profit before tax	(27,965)	(1,444)	46,179	1,874
Adjustments for :				
(Increase)/Decrease in trade and other receivables	-	-	164,313	8,829
Increase/(Decrease) in trade and other payables	(61,860)	(3,077)	(222,499)	(11,955)
	<b>(89,825)</b>	<b>(4,521)</b>	<b>(12,007)</b>	<b>(1,253)</b>
<b>Cash generated from operations</b>				
Direct taxes paid (net of refunds)	(15,601)	(776)	-	-
Interest paid	-	-	-	-
<b>Net cash inflow/(outflow) in course of operating activities</b>	<b>(105,426)</b>	<b>(5,297)</b>	<b>(12,007)</b>	<b>(1,253)</b>
<b>B. Cash flow arising from investing activities :</b>				
<b>Net cash inflow/(outflow) in course of investing activities</b>	-	-	-	-
<b>C. Cash flow arising from financing activities :</b>				
<b>Net cash inflow/(outflow) in course of financing activities</b>	-	-	-	-
<b>D. Foreign currency translation difference</b>		401		(600)
<b>Net Increase in cash &amp; cash equivalents (A+B+C)</b>	<b>(105,426)</b>	<b>(4,897)</b>	<b>(12,007)</b>	<b>(1,853)</b>
Add: cash and cash equivalents at the beginning of year	229,365	11,246	241,372	13,099
<b>Cash and cash equivalents at the close of the year</b>	<b>123,939</b>	<b>6,349</b>	<b>229,365</b>	<b>11,247</b>

Notes:

1) Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-" Cash Flow Statements".

2) Amounts in brackets are for cash outflows

**Prakash C Bisht**

CFO (Ingredients) & Sr. VP (Group Accounts)

Place: Noida

Date: 23 May, 2016

**JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC**
**Notes to the Financial Statements**

As at 31 March,	2016	2016	2015	2015
	CAD	INR (' In Thousands)	CAD	INR (' In Thousands)
<b>1. SHARE CAPITAL</b>				
<b>Authorized</b>				
	-	-	-	-
	-	-	-	-
	-	-	-	-
<b>Issued, Subscribed and Paid up</b>				
50,000 Equity Shares of CAD 1 Each (Previous Year 50,000 Equity Shares of CAD 1 each)	50,000	2,452	50,000	2,452
	<b>50,000</b>	<b>2,452</b>	<b>50,000</b>	<b>2,452</b>
<b>2. RESERVES AND SURPLUS</b>				
<b>Foreign Currency Translation Reserve</b>				
Foreign Currency Translation Reserve Opening	-	315	-	487
Foreign Currency Translation Reserve During the Year	-	329	-	(171)
	-	<b>644</b>	-	<b>315</b>
<b>Surplus as per P&amp;L Account</b>				
As per last Balance Sheet	94,186	4,302	60,429	3,054
Add: Net Profit after tax transferred from Statement of Profit and Loss	(27,965)	(1,444)	33,757	1,248
Amount available for appropriation	<b>66,221</b>	<b>2,858</b>	<b>94,186</b>	<b>4,302</b>
	<b>66,221</b>	<b>3,502</b>	<b>94,186</b>	<b>4,617</b>
<b>3. TRADE PAYABLES</b>				
Trade payables - micro enterprises and small enterprises	-	-	-	-
Trade payables-others	51	3	4,377	215
	<b>51</b>	<b>3</b>	<b>4,377</b>	<b>215</b>
<b>4. OTHER CURRENT LIABILITIES</b>				
Income received in advance/unearned revenue	5,499	281	63,034	3,091
Other payables	2,500	128	2,500	123
	<b>7,999</b>	<b>409</b>	<b>65,534</b>	<b>3,213</b>
<b>5. SHORT TERM PROVISIONS</b>				
Provision for income tax and wealth tax	-	-	15,269	749
	-	-	<b>15,269</b>	<b>749</b>

JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC

Notes to the Financial Statements

As at 31 March,	2016	2016	2015	2015
	CAD	INR (' In Thousands)	CAD	INR (' In Thousands)
<b>6. LONG TERM LOANS AND ADVANCES</b> <i>(Unsecured and considered good)</i>				
Advance payment of income tax/Wealth tax(including TDS)	332	17	-	-
	<b>332</b>	<b>17</b>	-	-
<b>7. CASH AND BANK BALANCES</b> Cash and cash equivalents <b>Balances with banks:</b> - On current accounts	123,939	6,349	229,365	11,246
	<b>123,939</b>	<b>6,349</b>	<b>229,365</b>	<b>11,246</b>

JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC

Notes to the Financial Statements

For the year ended 31 March,	2016	2016	2015	2015
	CAD	INR (' In Thousands)	CAD	INR (' In Thousands)
<b>8. REVENUE FROM OPERATIONS</b>				
Sales of services	57,535	2,840	154,155	7,763
<b>Revenue from operations(net)</b>	<b>57,535</b>	<b>2,840</b>	<b>154,155</b>	<b>7,763</b>
<b>9. OTHER INCOME</b>				
Other non-operating income	-	-	316	18
	-	-	<b>316</b>	<b>18</b>
<b>10. OTHER EXPENSE</b>				
Processing charges	76,802	3,855	89,624	4,941
Legal , professional and consultancy charges	7,401	365	7,961	416
Bank Charges	1,297	65	1,120	59
	<b>85,500</b>	<b>4,284</b>	<b>98,705</b>	<b>5,416</b>
<b>11. EXCEPTIONAL ITEMS</b>				
Foreign Exchange Loss	-	-	9,587	491
	-	-	<b>9,587</b>	<b>491</b>